2019 American Transplant Congress
Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
*Purpose: Tacrolimus (TAC) is part of the immunosuppression scheme of more than 95% of patients after kidney transplantation in Mexico. Low TAC tacrolimus trough levels…2019 American Transplant Congress
In Depth Look at Acute Rejections in LCP-Tacrolimus (LCPT; Envarsus XR) and Immediate-Release Tacrolimus (IR-Tac)-Treated De Novo Kidney Transplant Recipients
*Purpose: A prospective, randomized controlled trial has shown comparable rates of biopsy-proven rejection (BPAR) between LCPT and IR-Tac treated renal transplant recipients. This analysis aims…2019 American Transplant Congress
BK Virus Infection Disparity between Black and Other Races; Do Not Blame the Mycophenolic Acid
*Purpose: Disparities in kidney transplant outcomes between black recipients and others continue to exist. We sought to examine the impact of race and the differential…2019 American Transplant Congress
FK506 Influence Glucose Metabolism by Short Chain Fatty Acid
*Purpose: FK506 is one of the most common immunosuppressant drugs in organ transplantation, which have been demonstrated to cause glucose metabolism disorder and alterd the…2019 American Transplant Congress
Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients
*Purpose: The gut microbiota alters expression of drug-metabolizing enzymes and transporters, and consequently affects therapeutic dose and response of medicines. We aimed to investigate the…2019 American Transplant Congress
Not All Poor Metabolizers Are Clinically Equal: Evaluating Weight-Based Tacrolimus Outcomes in CYP3A Loss of Function Variants
Vidant Medical Center - Transplant Services, Greenville, NC
*Purpose: CYP3A polymorphisms are an important pharmacotherapeutic consideration due to the extensive CYP metabolism of tacrolimus (TAC) and variable expression among different races. The CPIC…2019 American Transplant Congress
mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis
*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…2019 American Transplant Congress
Increasing Time-in-Therapeutic Range of Tacrolimus is Associated with Superior Outcomes in Living Kidney Transplants
*Purpose: Tacrolimus-based regimens remain the backbone of maintenance immunosuppressive therapy in kidney transplant, and therapeutic drug monitoring of tacrolimus is necessary due to a narrow…2019 American Transplant Congress
CURATE.AI: Personalized Liver Transplant Tacrolimus Dosing
*Purpose: Transplant immunosuppressive regimens include multiple drugs with varying pharmacokinetics, metabolic pathways, and drug-drug interactions. This study aimed to use CURATE.AI, an artificial intelligence platform,…2019 American Transplant Congress
LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients
*Purpose: Different initial dosing strategies were studied in Phase II/Phase III trials evaluating the pharmacokinetics, safety, and efficacy of LCPT in de novo kidney transplantation.…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 14
- Next Page »